Information | NCP Flanders

Rare diseases

The partnership aims to improve the life of patients with rare diseases by developing diagnostics and treatments for rare diseases through multidisciplinary research & innovation programmes. The partneship started its activities in 2024.

The ERDERA partnership was launched in September 2024, with a budget of 380 million euros & uniting over 170 organisations. It will coordinate national, local and European research and innovation programmes, combining research funding and implementation of research supportive activities such as training, data access infrastructures, data standards etc.

The main goal is to improve the life of patients with rare diseases by developing diagnostics and treatments for rare diseases through multidisciplinary research and innovation programmes with all relevant stakeholders. This will increase impact and uptake of research results as well as increase the visibility of EU leadership in rare diseases research.

Past & current calls for proposals

Since it took off in 2024, ERDERA has launched 1 joint transnational call. ERDERA has announched it will soon launch it's first Clinical Trials call. Find out more on the funding page on the ERDERA website.

Timeline & key documents

More information on the partnership can be found in the draft outline of partnership proposal (February 2022).
A first version of the Strategic Research & Innovation Agenda that will underpin the Partnership was published in Spring 2023 in the context of a public consultation. The SRIA is yet to be finalised.
The partners involved in the European Joint Programme on Rare Diseases (EJP RD) have played an important role in the preparation of the SRIA.
The partnership proposal was submitted on 19 September 2023 for funding under Horizon Europe as a co-funded partnership between the European Commission, European Member States, and beyond.
The Partnership was launched in September 2024. Read all about it here.

Contact

Subscribe to the ERDERA newsletter here.

Contact ERDERA via the contact form on the ERDERA website: ERDERA - European Rare Diseases Research Alliance

Commission services: RTD-RD-PARTNERSHIP@ec.europa.eu

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

How to use partnerships?

orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.

networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.

ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.

steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

NCP Flanders

Updates

Funding programmes

About NCP Flanders

Content

Tools